Abigail Klein Mayo
Pharmaceutical Sciences PhD Candidate at the University of North Carolina at Chapel Hill. Anticipated graduation is August 2026.
About my research
About my research
Connect with me on LinkedIn!
Connect with me on LinkedIn!
Abigail Mayo CV
Document
Abigail Mayo CV
Publications
A novel differentiated HuH-7 cell model to examine bile acid metabolism, transport and cholestatic hepatotoxicity - PubMed
A novel differentiated HuH-7 cell model to examine bile acid metabolism, transport and cholestatic hepatotoxicity - PubMed
Hepatic cell lines serve as economical and reproducible alternatives for primary human hepatocytes. However, the utility of hepatic cell lines to examine bile acid homeostasis and cholestatic toxicity is limited due to abnormal expression and function of bile acid-metabolizing enzymes, transporters, …
The elucidation of species-specific receptor pharmacology: A case study using subtype-selective para- and meta-carborane estrogen receptor agonists - PubMed
The elucidation of species-specific receptor pharmacology: A case study using subtype-selective para- and meta-carborane estrogen receptor agonists - PubMed
Estrogen receptors (ERs) are essential pharmacological targets for treating hormonal disorders and estrogen-dependent malignancies. Selective activation of ERβ is hypothesized to provide therapeutic benefit with reduced risk of unwanted estrogenic side-effects associated with ERα activity. However, …
Species-Dependent Metabolism of a Covalent nsP2 Protease Inhibitor with In Vivo Antialphaviral Activity - PubMed
Species-Dependent Metabolism of a Covalent nsP2 Protease Inhibitor with In Vivo Antialphaviral Activity - PubMed
RA-0002034 (<b>1</b>) is a potent covalent inhibitor targeting the nsP2 cysteine protease. The species-dependent pharmacokinetics and metabolism of <b>1</b> were investigated to evaluate its therapeutic potential. Pharmacokinetic profiling revealed rapid clearance in mice, predominantly mediated by …
OSU-ERβ-12: a promising pre-clinical candidate selective estrogen receptor beta agonist - PubMed
OSU-ERβ-12: a promising pre-clinical candidate selective estrogen receptor beta agonist - PubMed
Estrogen receptor beta (ERβ) is a favorable therapeutic target for mediating inflammation, attenuating fibrosis, and treating cancer. However, selectively targeting ERβ over estrogen receptor alpha (ERα) has been a longstanding challenge. Recently, we developed OSU-ERβ-12, a novel carborane-based ER …
Email
Email
View on mobile
Explore other Linktrees
SAG Awards
@sagawards
Bits & Bites Blog
@bitsbitesblog
Autym
@autym
Substack
@substackinc
Kaitlyn Johnson
@missynjohnson
Alli Weatherly
@alliweatherly
jumperspodcast
@jumperspodcast
Gabby Windey
@gabbywindey
jenniferhudsonshow
@jenniferhudsonshow
Demi Lovato
@demilovato
previous
next
Discover more
See all
@historyontap
@ivancopelli
@ckgivan
@Judyschwind
@mellaenchanted
@orrinsuiteskl
@kazim.bakouza
@HubCaruci
@entrearquitectos
@Hope_plant1
@tellograciela22
@2Moshitos
@Im_asleep458
@flatcapjord
@Ydejesus.realtor
@Arepaplanet
@alnasr.sales
@sikumbul
@fleurs.world
@Neoki.io
@effata364
@Mazshoppaw
@BaskinDesign
@inhaleexhalecounseling
@mentalblazeretrozone
@Jaynightmare
@haciendobrands
@UniversoSkypper
@draanastaciasoares
@dynamicdetailingedmonton
@chibelsc
@conversationswmydaughter
@larajeong
@minute.tips2025
@offertastic
@Niyonizeyejoseph
@desmainspourtence
@ksa_vip2013
@airdropemirates
@adminpemesananyummy
@makeupmedsandmiracles
@mehzabeencoatwala
@spiriting_self
@santilistur
@CSNTSTORE
✕